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Cost effectiveness analysis in cystic fibrosisIn the current issue of the journal, Thornton et al. (2005)
report the results of a cost-effectiveness analysis (CEA) of
using home-based and hospital-based treatment with intra-
venous antibiotic for respiratory exacerbations in adults with
CF [1]. The term cost-effectiveness has been used more
frequently over the past two decades as pressures to control
health care spending have accelerated [2]. CEA provides an
explicit framework for assessing value for money of
competing health care interventions and is therefore seen
as an aid to the decision-making process. The central
purpose of CEA is to compare the relative value of different
interventions in creating better health and/or longer life [3].
The results of such evaluations are typically summarized in
a cost-effectiveness ratio, where the denominator reflects the
gain in health from a candidate interventions (measured as
units natural to the program at hand such as life years
gained) and the numerator reflects the cost of obtaining that
health gain. A variant of CEA, cost-utility analysis (CUA)
measures the gain according to health state preference
scores or utility weights thus providing an opportunity to
measure the quality of life years gained not just the crude
number of years [3].
Given the rise in popularity in the use of economic
evaluations, guidelines have been developed to improve
the methodological rigour, and hence comparability, of
each evaluation. Two of the more commonly cited
references are the Washington Consensus Panel on Cost-
Effectiveness in Health and Medicine [2] and a textbook
by Drummond [3]. Both provide recommendations for the
conduct of economic evaluations in order to improve their
quality. Drummond has developed a checklist for assessing
economic evaluation that provides useful guidance for
those undertaking their own study [3]. It is in the general
context of these guidelines that we discuss the manuscript
by Thornton et al. [1].
1. Was a well-defined question posed in answerable
form?
Adults with CF experience repeated infective respiratory
exacerbations leading to continued decline in lung function.
Given that the standard treatment for exacerbations is
intravenous antibiotics, the research question of examining1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.09.006the costs and consequences of home versus hospital-based
treatment is appropriate, relevant and explicitly stated.
2. Was a comprehensive description of the competing
alternatives given?
A general description of the setting, type of participants
and levels of care is outlined for each mode of delivery and
provide the reader with enough information to comprehend
the scope of the research brief.
3. Was the effectiveness of the program established?
The primary clinical outcome adopted for the economic
evaluation was forced expiratory volume in 1 s (FEV1). A
course of treatment was defined as effective if baseline lung
function was maintained, i.e., the percentage decline in
FEV1 was V0%. In a sensitivity analysis, a less stringent
definition of effectiveness was also explored: V2% decline
in FEV1.
4. Were all the important and relevant costs and
consequences for each alternative identified?
Thornton et al. (2005) adopts the viewpoint of the health
care provider (NHS trust) [1]. Although economists
consider a societal perspective desirable, the adoption of a
more restricted perspective is appropriate. In line with the
chosen viewpoint, the authors have limited their cost
estimates to those associated with infection management
in hospital. The use of FEV1 as the measure of effectiveness
provides a useful metric to compare modes of treatment.
5. Were costs and consequences measured accurately in
appropriate physical units?
Appropriate techniques (given the perspective) were used
to measure resource use and outcome. For example, staff
time with patients was measured using time sheets, medi-
cation use was collected from clinical records and hospital
costs were measured using financial records. Program
effectiveness was measured using spirometric testing.
6. Were costs and consequences valued credibly?
All costs were calculated for the year 2002 and reported
in UK sterling. Although the unit costs of each resource
item are not presented, the value of these items were
obtained from the NHS trust including the specific CF Unit
budget, the British National Formulary and the hospital
supplies catalogue.4 (2005) 211–212ed by Elsevier B.V. All rights reserved.
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timing?
It is common practice in economic evaluation to discount
future dollar costs and benefit streams to reflect that money
spent or saved in the future should not weigh as heavily in
program decisions as money spent or saved today. Dis-
counting is not appropriate in the current study given that
costs and consequences were restricted to one year.
8. Was an incremental analysis of costs and consequen-
ces of alternatives performed?
As correctly pointed out by the authors, the incremental
cost effectiveness ratio (ICER) is the ratio of the differences
in cost to the differences in effectiveness between treatment
options. The ICER in this context provides an indication of
the additional cost of achieving a percentage reduction in
FEV1 in one setting compared to standard setting. The
authors report in the text that it costs o42,048 to achieve one
additional effective course of treatment (i.e., V0% FEV1) in
hospital compared with at home.
9. Was allowance made for uncertainty in the estimates
of costs and consequences?
Over the last decade extensive testing of the sensitivity of
cost-effectiveness results to variations in assumptions
around the input cost and epidemiological variables has
become possible due to improvements in computing
technology. The bootstrapping techniques used are appro-
priately used and presented in cost-effectiveness planes and
an acceptability curve.
10. Did the presentation and discussion of study results
include all issues of concern to users?
The authors provide a discussion of their findings in the
context of study limitations and existing literature. The
authors present and interpret their results in a manner in
which policy makers can comprehend. One point of
clarification, however, is in the interpretation of accept-
ability of cost-effectiveness to policy makers. The National
Institute of Clinical Excellence state that an ICER of
bo20,000 QALY is considered to be cost-effective[4,5]. If
it were possible to replace QALY with the intermediate
outcome of FEV1, the current interventions would not
satisfy the criteria of cost-effectiveness. The authors also
undertake uncertainty analysis by examining the impact of
adopting a less stringent effectiveness measure (V2% in
FEV1) on the ICER and also couch the findings in terms of
acceptability to policy makers. Key recommendations are
also provided by the authors.
By considering the Thornton et al. (2005) manuscript in
the context of guidelines for appraising economic evaluation,
the intention has been to provide the reader with an insight
into the methodological challenges underpinning such an
analysis. Three important aspects are worth reflecting on.
First, the perspective adopted for an economic evaluation
needs to reflect the purpose of the research. A socialperspective is considered the ideal since it aims to capture
the full extent of resource use associated with competing
health care interventions thus providing a more accurate
estimate of the true economic cost to society. Second, the use
of a more final outcome measure such as the QALY is
becoming more common in economic evaluations due to the
importance of measuring improvements (or reductions) in
patient quality and quality of life and the need for
comparability across multiple health care programs. Third,
uncertainty modelling is crucial to examining the robustness
of results to variations in parameters, model specification
and time horizons. In particular, economic and epidemio-
logical modelling is now used extensively to broaden the
time horizon [6].
In summary, CEA is an acceptable and useful tool to
assist decision makers allocate resources across competing
health care interventions. The rise in popularity in the use of
CEA has fostered the development of guidelines to improve
the methodological rigour and comparability of evaluations.
It is hoped that better adherence of these guidelines will
improve the calibre of such appraisals and encourage more
effective communication between researchers, clinicians
and policy makers.References
[1] Thornton J, Elliot RA, Tully MP. Clinical and economic choices in
the treatment of respiratory infections in cystic fibrosis: comparing
hospital and home care. J Cyst Fibros 2005—2005;4:239–47 (this
issue). doi:10.1016/j.jcf.2005.08.003.
[2] Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effective-
ness in health and medicine. New York7 Oxford University Press;
1996.
[3] Drummond M, O’Brien B, Stoddart G, Torrance G. Methods for the
economic evaluation of health care programmes. Oxford7 Oxford
University Press; 1987.
[4] National Institute for Clinical Excellence. A guide for manufacturers
and sponsors: contributing to a technical appraisal. London7 NICE;
2004.
[5] National Institute for Clinical Excellence. Guide to the methods of
technology appraisal. London7 NICE; 2004.
[6] Liew D, McNeil J, Peeters A, Lim SS, Vos T. Epidemiological
modelling (including economic modelling) and its role in preventive
drug therapy. MJA 2002;177:364–7
Chris Doran
School of Population Health, School of Economics,
University of Queensland, Australia
E-mail address: c.doran@sph.uq.edu.au.
Corresponding author.
Theo Vos
School of Population Health,
University of Queensland, Australia
E-mail address: t.vos@sph.uq.edu.au.
